Treatment and diagnosis history, and response to targeted therapy, of a patient with pancreatic adenocarcinoma with an EGFR exon19 deletion. Treatment.

Slides:

Advertisements

Similar presentations

DOWNSTAGING LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA (LAPC) WITH VASCULAR ENCASEMENT USING PERCUTANEOUS IRREVERSIBLE ELECTROPORATION (IRE) NARAYANAN,GOVINDARAJAN;

Advertisements

Imaging Metastatic Rectal Cancer Jack Temple, MS3 June 2013 Christian Malalis, MD.

PET in Colorectal Cancer. Indications for FDG PET Rising marker, (-) CT/MRI Nonspecific findings on CT/MRI, recurrence or post treatment changes? Known.

Chemotherapy for Liver Metastasis Originating from Colorectal Cancer with Portal Vein Tumor Thrombosis: A Case Report Case Rep Oncol 2013;6:

Progressive brain metastases in an EGFR mutated adenocarcinoma of the lung: Response to gefitinib after progression on erlotinib C. Leitner, R. von Moos,

Illustration of a pure ground-glass nodule which developed a solid component. a) June 2004; b) October 2004; c) June 2005; d) July Illustration of.

Fig. 2. Atypical response to VEGF-targeted therapy in colon cancer

A 30 year old man with headaches, imbalance and aphasia

A proposed treatment model for the decision-making process when choosing between cetuximab continuation vs rechallenge. aTypically patients with left-sided,

A, baseline and 4-week PET scan from patient 2 (MET c

Staging of Pancreatic Adenocarcinoma by Imaging Studies

Nat. Rev. Urol. doi: /nrurol

PD-1 and LAG-3 expression in MSI and MSS colorectal cancer specimens.

Patient-Centered Management in Pancreatic Cancer

A 30-year-old man with PSA

123I/Tc-99m sestamibi subtraction scan (top left); neck sonogram in region of cystic mass (top right); axial arterial phase CT scan (bottom left); and.

Images from the case of a 62-year-old man with malignant lymphoma

Successful tissue collection in patients with relapse of EGFR-positive adenocarcinoma after EGFR-TKI treatment. Successful tissue collection in patients.

Example of pretreatment (A and B) and 8-week posttreatment (C and D) PET CT images. Example of pretreatment (A and B) and 8-week posttreatment (C and D)

Management of Advanced Pancreatic Adenocarcinoma

Representative CT and PET/CT images of three patients with NSCLCs

Algorithms for the management of metastatic colorectal cancer: (A) resectable metastatic disease; (B) metastatic disease, first-line; (C) metastatic disease,

Coexistence of Tyrosine Kinase Inhibitor-Sensitizing and Resistant EGFR Mutations in an Untreated Lung Adenocarcinoma Patient and Response to Erlotinib

CT Characteristics and Pathologic Basis of Solitary Cystic Lung Cancer

Case 1, extranodal orbital involvement in Rosai-Dorfman disease.

Examples of 2 patients with lesions visible only in the DIR images and not in the T2WI TSE images. Examples of 2 patients with lesions visible only in.

Figure Genetic deletion and MRI changes with EHMT1 deletion

Osteoblastic Bone Lesions Developing During Treatment with Erlotinib Indicate Major Response in Patients with Non-small Cell Lung Cancer: A Brief Report

Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.

A, In a patient with a history of breast cancer surgery and radiation treatment with right-arm weakness, axial T2WI shows diffuse thickening of the right.

A 62-year-old man with subacute cognitive impairment and seizures.

Axial CT images of midthoracic lesions

A and B, Axial and coronal high-resolution CT images of the larynx in a 73-year-old patient with papillary thyroid cancer and left vocal cord paralysis.

Perfusion CT to Assess Response to Neoadjuvant Chemotherapy and Radiation Therapy in Pancreatic Ductal Adenocarcinoma: Initial Experience After neoadjuvant.

Image-guided Irreversible Electroporation of Localized Prostate Cancer: Functional and Oncologic Outcomes Following irreversible electroporation (IRE)

Coronal (A) and axial (B) contrast-enhanced T1-weighted MR images and an axial DWI (C) and ADC map (D) in a patient with primary dural B-cell lymphoma.

Mass was believed to represent a submandibular space or gland tumor by the referring general surgeon, who initially planned to excise the mass. Mass was.

PCT imaging with ICA reference of a patient with right tongue base squamous cell carcinoma. PCT imaging with ICA reference of a patient with right tongue.

A 50-year-old man with adenocarcinoma of the left lacrimal sac and nasolacrimal duct. A 50-year-old man with adenocarcinoma of the left lacrimal sac and.

Representative examples of estrogen receptor α and β immunohistochemical expression (top figures) and EGFR mutations (bottom figures) in lung adenocarcinomas.

A and B, CT images on a patient status post total thyroidectomy for thyroid cancer show a small enhancing lesion near the right tracheoesophageal groove.

KIT mutations in GISTs. A, amino acid sequence of KIT exon 11 mutations in clinical GIST biopsies. –, amino acids that are deleted; italicized amino acids,

Oblique axial computed tomography (CT) reformatted image perpendicular to the superior mesenteric artery axis demonstrating swirling of the mesenteric.

Representative CT and PET/CT images of three patients with NSCLCs

A, Coronal enhanced MR image of an IAC meningioma demonstrates intense enhancement of the intralabyrinthine structures (curved white arrow). A, Coronal.

Contrast-agent–enhanced T1-weighted MR images (700/15) obtained in a 71-year-old man with skin cancer, who had TMJ tenderness and discomfort in the left.

Bone algorithm CT images from the same case, demonstrating focal enlargement of the right tympanic segment, in the axial (left) and coronal (right) planes.

Plasma and tissue EGFR allele analyses.

Delineation of the clinical course and evolution of BRAF mutation status in the seven patients with BRAF V600E mutation. Delineation of the clinical course.

Duration of treatment and intervals of radiographic and ctDNA response

Imaging studies in patients attaining objective response on phase I study. Imaging studies in patients attaining objective response on phase I study. A,

The classic CT and MR imaging appearance of an astroblastoma in a 5-year-old female patient (patient 4).A, Axial non-contrast-enhanced CT scan shows the.

Serial chest CT scans of 33-year-old male with lung adenocarcinoma harboring EGFR-KDD documenting response to afatinib and subsequent acquired resistance.

Noninvasive detection of acquired MET amplification as a mechanism of afatinib/trastuzumab resistance using cfDNA. Noninvasive detection of acquired MET.

A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma.

Molecular heterogeneity drives secondary resistance to anti-EGFR therapies in mCRC. Molecular heterogeneity drives secondary resistance to anti-EGFR therapies.

Efficacy summary for patients with gastric/GEJ adenocarcinoma (part B)

Change in FES uptake in the tumor during fulvestrant treatment.

Frequent coamplification of RTKs in MET-amplified EGC

Patient 10. Patient 10. A 67-year-old man after radiation therapy at an outside hospital for base-of-tongue cancer. A and B, Axial contrast-enhanced CT.

Rapid autopsy reveals interlesional and intralesional heterogeneity of resistance. Rapid autopsy reveals interlesional and intralesional heterogeneity.

Serial CT scan images from patient with a partial response.

Response to crizotinib in an 8-year-old boy with refractory IMT harboring a TFG–ROS1 fusion. Response to crizotinib in an 8-year-old boy with refractory.

BRAF in-frame deletion confers response to MAPK inhibition.

Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy. Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy.

A, study design for measuring the feasibility, concordance, and accuracy of a plasma-based cfDNA sequencing test compared with biopsy-based sequencing.

Single-site disease progression after 9 months of response to therapy in the right hemipelvis visualized by diffusion-weighted whole-body MRI. Top, fusion.

Patient 4, a 72-year-old man presenting with headache, dysphagia, and progressive hoarseness. Patient 4, a 72-year-old man presenting with headache, dysphagia,

KD involving bilateral buccal spaces in a 52-year-old man.

50-year-old woman with history of left parieto-temporo-occipital glioblastoma multiforme and new abnormal enhancement on follow-up imaging after surgery.

Presentation transcript:

Treatment and diagnosis history, and response to targeted therapy, of a patient with pancreatic adenocarcinoma with an EGFR exon19 deletion. Treatment and diagnosis history, and response to targeted therapy, of a patient with pancreatic adenocarcinoma with an EGFR exon19 deletion. A, CA 19-9 levels (x-axis) over time of treatment (y-axis) for patient #34. Dates of two biopsy-based NGS tests, and of EGFR indel detection by cfDNA test, are indicated along the CA 19-9 line. Time intervals for therapies administered to patient are indicated by bracketed lines at top. Erlotinib monotherapy is ongoing as of June 3, 2015. B, axial (top) and coronal (bottom) contrast-enhanced CT images from October 2014 demonstrate infiltrative tumor (arrows) arising from the pancreatic body and encasing the celiac axis. C, axial (top) and coronal (bottom) contrast-enhanced CT images from February 2015 demonstrate marked reduction in the size of the pancreatic mass. FOLFIRINOX, Leucovorin Calcium (Folinic Acid), Fluorouracil, Irinotecan Hydrochloride, Oxaliplatin; CAPOX, Capecitabine and Oxaliplatin. Oliver A. Zill et al. Cancer Discovery 2015;5:1040-1048 ©2015 by American Association for Cancer Research